Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
| 8.97 Data as of Jul 28 |  +0.03 / +0.34%Today’s Change | 5.84 Today|||52-Week Range 11.47 | +18.97% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2010 | 2011 | 2012 | 2013 | |||
| Revenue and Income | Net Revenues | 106.0K | 803.0K | 1.5M | 12.0M | |
| Cost of Goods Sold | 34.0M | 29.7M | -- | 362.0K | ||
| Depreciation And Amortization | 1.2M | 879.0K | 871.0K | 742.0K | ||
| Operating Expenses | Gross Income | -35.0M | -29.8M | -- | 10.9M | |
| General Expenses | 5.1M | 7.9M | 42.8M | 72.8M | ||
| Research And Development | -- | -- | 23.5M | 17.2M | ||
| Total Operating Expenses | 40.2M | 38.6M | 43.6M | 73.9M | ||
| Non-Operating Expenses | Operating Income | -40.1M | -37.8M | -42.2M | -61.9M | |
| Extraordinary Charge | 0.00 | 0.00 | 0.00 | -22.9M | ||
| Interest Expense On Debt | 0.00 | 1.9M | 3.6M | 7.8M | ||
| Other Expenses | 542.0K | 117.0K | -660.0K | 101.0K | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -39.5M | -39.5M | -46.3M | -92.3M | |
| Income Taxes | -399.0K | -16.2M | 0.00 | 0.00 | ||
| Preferred Dividend | -3.4M | -3.4M | -1.1M | 0.00 | ||
| Discontinued Operations | 612.0K | 2.2M | 0.00 | 0.00 | ||
| Extraordinary Items | 0.00 | 74.9M | 0.00 | 0.00 | ||
| Net Income | -38.5M | -21.0M | -46.3M | -92.3M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 23.9M | 23.9M | 17.4M | 31.8M | |
| Shares To Calculate EPS Diluted | 23.9M | 23.9M | 17.4M | 31.8M | ||
| Earnings Per Share | EPS | -$26.38 | $31.39 | -$2.72 | -$2.90 | |
| EPS Diluted | -$1.75 | -$1.02 | -$2.72 | -$2.90 | ||
.
